AUSTIN, Texas—Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), recently executed a significant transaction involving the company's stock. According to a Form 4 filing with the Securities and Exchange Commission, Moshkevich sold 4,858 shares of Natera's common stock on December 9, 2024, at a weighted average price of $166.5937 per share. This sale amounted to a total value of approximately $809,312. The transaction comes as Natera's stock trades near its 52-week high of $175.63, having delivered an impressive 185% return over the past year, according to InvestingPro data.
In addition to the sale, Moshkevich also acquired shares through the exercise of stock options. He acquired 5,752 shares at a price of $7.4491 per share and an additional 3,323 shares at $12.8501 per share. The total value of these acquisitions was $85,548. The sale of shares was part of a strategy to satisfy tax withholding obligations related to the exercise of options, in compliance with Rule 10b5-1.
Following these transactions, Moshkevich holds a total of 114,912 shares of Natera's common stock.
In other recent news, Natera Inc (NASDAQ:NTRA). reported record Q3 revenue of $439.8 million, a 64% increase year-over-year, and conducted 137,000 oncology tests, marking a 54% increase from the previous year. The company's gross margins reached a record high of 62%, leading to a revision of its full-year revenue guidance to between $1.61 billion and $1.64 billion. Natera's Signatera test, a major revenue contributor, showed promising results in predicting survival and chemotherapy benefits in colorectal cancer.
In the backdrop of these robust financial results, analyst firms TD (TSX:TD) Cowen, Baird, and Jefferies have maintained favorable ratings on Natera's stock and raised their price targets. In other developments, Natera amended its agreement with Executive Chairman Dr. Rabinowitz, who will continue his role on an at-will basis, with an annual base salary set at half of the company's CEO's base salary.
However, Natera faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH), but the company remains firm in its disagreement with the decision. These are some of the recent developments shaping the trajectory of Natera Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.